No Data
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
BeiGene to Rebrand as BeOne Medicines With Oncology-Focused New Nasdaq Ticker "ONC"
Express News | Beigene - Will Change Its Nasdaq Ticker Symbol for Its American Depositary Shares From "Bgne" to "Onc" on Jan 2, 2025
BEIGENE (688235.SH): Plans to change the company's Nasdaq stock code to "ONC".
Gelonghui, December 23rd ┃ BEIGENE (688235.SH) announced that the company's American depositary shares traded on Nasdaq will change their stock code from "BGNE" to "ONC," effective from January 2, 2025, to emphasize the company's firm commitment to providing innovative oncology drugs globally. The stock code and abbreviated name on the Shanghai Stock Exchange and the stock code and abbreviated name on the Hong Kong Stock Exchange will remain unchanged. The change of the Nasdaq stock code can be implemented without submission for discussion at the company’s shareholder meeting.
BeiGene to Change Nasdaq Ticker Symbol to "ONC" on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
Express News | Beigene to Change Nasdaq Ticker Symbol to “Onc” on January 2; Present at 43Rd Annual J.P. Morgan Healthcare Conference
